Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical hematopoietic stem cells + umbilical cord blood
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Haploidentical hematopoietic stem cells combined with umbilical cord blood (often referred to as a 'haplo-cord' transplant) is an investigational cellular therapy approach developed at Weill Medical College of Cornell University. The procedure involves the co-infusion of CD34+ selected progenitor cells from a partially matched (haploidentical) related donor alongside a unit of umbilical cord blood. This approach is designed to overcome the slow engraftment typically associated with cord blood transplants by using the haploidentical cells for rapid initial neutrophil and platelet recovery, while the cord blood provides durable long-term hematopoiesis and a potent graft-versus-leukemia effect. It is primarily indicated for patients with high-risk hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), who lack a human leukocyte antigen (HLA)-identical donor.
- Other names
- haplo-cord transplanthaplo-cord graftcombined haplo-identical umbilical cord blood transplantationhaplo-cord
Beyond the preview
Go deeper on haploidentical hematopoietic stem cells + umbilical cord blood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical hematopoietic stem cells + umbilical cord blood.